MacroGenics, a clinical-stage biotech developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. The Rockville, MD-based company, which was founded in 2000 and booked $49 million in grant and collaboration revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol MGNX. MacroGenics initially filed confidentially on August 2, 2013. BofA Merrill Lynch and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.
